Literature DB >> 12610821

Early predictors of longterm outcome in patients with juvenile rheumatoid arthritis: subset-specific correlations.

Kiem Oen1, Peter N Malleson, David A Cabral, Alan M Rosenberg, Ross E Petty, Martin Reed, Marlis L Schroeder, Mary Cheang.   

Abstract

OBJECTIVE: To determine early predictors of longterm outcome in juvenile rheumatoid arthritis (JRA) in a multicenter cohort.
METHODS: Patients were selected if they were > or = 8 years of age; the onset of arthritis occurred > or = 5 years before study; and a diagnosis of JRA was made at a participating center. Outcome variables were scores on self-administered Childhood Health Assessment Questionnaires (CHAQ) and active disease duration. Possible explanatory variables assessed included characteristics present at onset, HLA alleles, in particular the rheumatoid arthritis associated shared epitope (RASE), and radiographic indicators of joint damage within 2 years of onset. Data for 393 patients were available. Multivariate analyses were performed for the total group and for each onset subtype.
RESULTS: Male sex correlated with worse disability in systemic onset JRA but less disability in RF negative, and a shorter active disease duration in RF positive polyarticular onset JRA. Positive antinuclear antibody correlated with a longer active disease duration in patients with pauciarticular onset JRA. Younger age at onset predicted longer active disease duration in pauciarticular and RF negative polyarticular, and a shorter active disease duration in systemic onset JRA. Residence on a reserve, rather than native North American race, correlated with worse disability. The RASE correlated with less disability in systemic JRA; but no correlation with outcome was evident for patients with rheumatoid factor positive polyarticular JRA.
CONCLUSION: Variables predictive of longterm outcome in JRA are specific for each onset subtype. The most important early predictors were age at onset and sex of the patient. Place of residence may have a greater effect on disability than race. RASE may associate with a more favorable outcome in systemic onset disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610821

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  20 in total

1.  Elevated IgG autoantibody production in oligoarticular juvenile idiopathic arthritis may predict a refractory course.

Authors:  M L Stoll; Q-Z Li; J Zhou; M Punaro; N J Olsen
Journal:  Clin Exp Rheumatol       Date:  2011-09-01       Impact factor: 4.473

2.  Antinucleosome antibodies in juvenile chronic arthritis.

Authors:  Renato M Nisihara; Thelma Skare; Marilia Barreto Silva; Rafael Mourato Silva; Danilo J Munhoz Silva
Journal:  Clin Rheumatol       Date:  2009-09-30       Impact factor: 2.980

3.  Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states.

Authors:  Claudia Macaubas; Khoa Nguyen; Chetan Deshpande; Carolyn Phillips; Ariana Peck; Tzielan Lee; Jane L Park; Christy Sandborg; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2009-10-29       Impact factor: 3.969

4.  Clinical and associated inflammatory biomarker features predictive of short-term outcomes in non-systemic juvenile idiopathic arthritis.

Authors:  Elham Rezaei; Daniel Hogan; Brett Trost; Anthony J Kusalik; Gilles Boire; David A Cabral; Sarah Campillo; Gaëlle Chédeville; Anne-Laure Chetaille; Paul Dancey; Ciaran Duffy; Karen Watanabe Duffy; John Gordon; Jaime Guzman; Kristin Houghton; Adam M Huber; Roman Jurencak; Bianca Lang; Kimberly Morishita; Kiem G Oen; Ross E Petty; Suzanne E Ramsey; Rosie Scuccimarri; Lynn Spiegel; Elizabeth Stringer; Regina M Taylor-Gjevre; Shirley M L Tse; Lori B Tucker; Stuart E Turvey; Susan Tupper; Rae S M Yeung; Susanne Benseler; Janet Ellsworth; Chantal Guillet; Chandima Karananayake; Nazeem Muhajarine; Johannes Roth; Rayfel Schneider; Alan M Rosenberg
Journal:  Rheumatology (Oxford)       Date:  2020-09-01       Impact factor: 7.580

5.  Ocular morbidities of juvenile idiopathic arthritis-associated uveitis in adulthood: results from a tertiary center study.

Authors:  Merih Oray; Naira Khachatryan; Nazanin Ebrahimiadib; Khawla Abu Samra; Stacey Lee; C Stephen Foster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-15       Impact factor: 3.117

6.  Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.

Authors:  Marion A J van Rossum; Renée M van Soesbergen; Maarten Boers; Aeilko H Zwinderman; Theo J W Fiselier; Marcel J A M Franssen; Rebecca ten Cate; Lisette W A van Suijlekom-Smit; Nico M Wulffraat; Wilma H J van Luijk; Johanna C M Oostveen; Wietse Kuis; Ben A C Dijkmans
Journal:  Ann Rheum Dis       Date:  2007-05-09       Impact factor: 19.103

7.  [Remission in pediatric rheumatology].

Authors:  H-L Huppertz
Journal:  Z Rheumatol       Date:  2013-05       Impact factor: 1.372

8.  Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2-10-year Etanercept exposure.

Authors:  Maria Trachana; Polyxeni Pratsidou-Gertsi; Maria Badouraki; Anna Bettina Haidich; Grigoris Pardalos
Journal:  Clin Rheumatol       Date:  2013-04-19       Impact factor: 2.980

Review 9.  Judicious use of biologicals in juvenile idiopathic arthritis.

Authors:  Yongdong Zhao; Carol Wallace
Journal:  Curr Rheumatol Rep       Date:  2014-11       Impact factor: 4.592

10.  Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study.

Authors:  Kimme L Hyrich; Sham D Lal; Helen E Foster; Judith Thornton; Navid Adib; Eileen Baildam; Janet Gardner-Medwin; Lucy R Wedderburn; Alice Chieng; Joyce Davidson; Wendy Thomson
Journal:  Rheumatology (Oxford)       Date:  2009-11-19       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.